Please assess the completion status of the following clinical trial:

Trial Title: Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Newly diagnosed high-grade glioma, including the following subtypes:~  * Anaplastic astrocytoma~ * Anaplastic oligodendroglioma~ * Glioblastoma multiforme~* Requires dexamethasone at a dose of \> 4 mg/day to control symptoms of tumor-related edema at time of study enrollment AND has been on a stable dose of steroids for ≥ 5 days prior to study enrollment~* Completed ≥ 80% of prescribed radiotherapy~* Hypogonadal, defined as serum testosterone level \< 350 ng/dL~* No history of prostate or breast cancer~* No benign prostatic hypertrophy requiring therapy OR AUA score of ≥ 8~  * PSA ≤ 4 ng/mL~PATIENT CHARACTERISTICS:~* Karnofsky performance status 60-100%~* Able to keep daily records or has a care provider that agrees to keep daily records of drug administration~* No clinical history of congestive heart failure requiring therapy~* No psychotic disorder requiring active treatment~* No structured exercise program involving exercise for \> 3 hours/week~* No polycythemia (i.e., hematocrit \> 52%)~PRIOR CONCURRENT THERAPY:~* More than 6 months since prior androgen therapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Control Group (Type: PLACEBO_COMPARATOR): whey protein powder
- ARM 2 : Treatment Group (Type: ACTIVE_COMPARATOR): Testosterone Gel (10g pouch/day) applied to skin

Based on this trial design, predict the completion outcome and termination type (if applicable).